Apoptosis may be an early event of progestin therapy for endometrial hyperplasia

Charlie A. Amezcua, Jean J. Lu, Juan C. Felix, Frank Z. Stanczyk, Wenxin - Zheng

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. The aim of this study was to investigate the role of apoptosis during progestin therapy for the treatment of endome-trial hyperplasia. Methods. Pre- and posttreatment paraffin-embedded endome-trial tissue samples from 19 Women with endometrial hyperplasia were examined for changes in glandular cellularity and apoptotic activity related to the administration of progestins. Twelve patients were successfully treated with progestin therapy and 7 patients failed treatment. Glandular cellularity was assessed based on calculating the average number of cells per gland obtained on histologic examination of hematoxylin and eosin stained tissue sections. Apoptotic activity was assessed on the same tissue sections by counting the average number of apoptotic cells per 10 high power fields (hpf) using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The effects of progesterone on apoptotic activity in a low-grade endometrial adenocarcinoma cell line (Ishikawa cells) was also examined using an ELISA cell death detection kit. Results. Glandular cellularity significantly decreased with pro-gestin therapy in both treatment outcome groups. The reduction in cells per gland was significantly greater in the group of successfully treated cases compared to the treatment failures (P = 0.005). However, within the successfully treated group, in situ detection of apoptotic cells using the TUNEL assay showed no statistical difference between pre- and posttreatment endometrial samples. Interestingly, a significant decrease in apoptosis was found in posttreatment samples of the group with persistent hyperplasia. The average number of apoptotic cells detected in 10 hpf was reduced from 7.9 prior to treatment to 3.1 after progestin therapy (P = 0.03). In the progesterone-treated Ishikawa cell line, an increase in apoptotic activity started at 24 h, reached a peak at 48 h, and continued up to 72 h of hormone treatment. At 48 h, apoptotic activity was 42.6% greater than in the untreated control (P = 0.04). By 72 h of progesterone treatment, apoptosis was 37.2% greater in the treated cells compared to the noninoculated cells (P = 0.04). Conclusions. Progestin-induced apoptosis may occur during the early period of treatment for endometrial hyperplasia. Compared to the fully responsive group, persistent endometrial hyperplasia may have intrinsically different molecular mechanisms in response to progestin therapy. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalGynecologic Oncology
Volume79
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Endometrial Hyperplasia
Progestins
Apoptosis
Therapeutics
Progesterone
Cell Count
Hyperplasia
Cell Line
DNA Nucleotidylexotransferase
Hematoxylin
Eosine Yellowish-(YS)
Transferases
Treatment Failure
Paraffin
Adenocarcinoma
Cell Death
Enzyme-Linked Immunosorbent Assay

Keywords

  • Apoptosis
  • Endometrial cancer
  • Endometrial hyperplasia
  • Progestin

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. / Amezcua, Charlie A.; Lu, Jean J.; Felix, Juan C.; Stanczyk, Frank Z.; Zheng, Wenxin -.

In: Gynecologic Oncology, Vol. 79, No. 2, 2000, p. 169-176.

Research output: Contribution to journalArticle

Amezcua, Charlie A. ; Lu, Jean J. ; Felix, Juan C. ; Stanczyk, Frank Z. ; Zheng, Wenxin -. / Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. In: Gynecologic Oncology. 2000 ; Vol. 79, No. 2. pp. 169-176.
@article{e56eeea963364333acbda65098e89b49,
title = "Apoptosis may be an early event of progestin therapy for endometrial hyperplasia",
abstract = "Objective. The aim of this study was to investigate the role of apoptosis during progestin therapy for the treatment of endome-trial hyperplasia. Methods. Pre- and posttreatment paraffin-embedded endome-trial tissue samples from 19 Women with endometrial hyperplasia were examined for changes in glandular cellularity and apoptotic activity related to the administration of progestins. Twelve patients were successfully treated with progestin therapy and 7 patients failed treatment. Glandular cellularity was assessed based on calculating the average number of cells per gland obtained on histologic examination of hematoxylin and eosin stained tissue sections. Apoptotic activity was assessed on the same tissue sections by counting the average number of apoptotic cells per 10 high power fields (hpf) using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The effects of progesterone on apoptotic activity in a low-grade endometrial adenocarcinoma cell line (Ishikawa cells) was also examined using an ELISA cell death detection kit. Results. Glandular cellularity significantly decreased with pro-gestin therapy in both treatment outcome groups. The reduction in cells per gland was significantly greater in the group of successfully treated cases compared to the treatment failures (P = 0.005). However, within the successfully treated group, in situ detection of apoptotic cells using the TUNEL assay showed no statistical difference between pre- and posttreatment endometrial samples. Interestingly, a significant decrease in apoptosis was found in posttreatment samples of the group with persistent hyperplasia. The average number of apoptotic cells detected in 10 hpf was reduced from 7.9 prior to treatment to 3.1 after progestin therapy (P = 0.03). In the progesterone-treated Ishikawa cell line, an increase in apoptotic activity started at 24 h, reached a peak at 48 h, and continued up to 72 h of hormone treatment. At 48 h, apoptotic activity was 42.6{\%} greater than in the untreated control (P = 0.04). By 72 h of progesterone treatment, apoptosis was 37.2{\%} greater in the treated cells compared to the noninoculated cells (P = 0.04). Conclusions. Progestin-induced apoptosis may occur during the early period of treatment for endometrial hyperplasia. Compared to the fully responsive group, persistent endometrial hyperplasia may have intrinsically different molecular mechanisms in response to progestin therapy. (C) 2000 Academic Press.",
keywords = "Apoptosis, Endometrial cancer, Endometrial hyperplasia, Progestin",
author = "Amezcua, {Charlie A.} and Lu, {Jean J.} and Felix, {Juan C.} and Stanczyk, {Frank Z.} and Zheng, {Wenxin -}",
year = "2000",
doi = "10.1006/gyno.2000.5955",
language = "English (US)",
volume = "79",
pages = "169--176",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Apoptosis may be an early event of progestin therapy for endometrial hyperplasia

AU - Amezcua, Charlie A.

AU - Lu, Jean J.

AU - Felix, Juan C.

AU - Stanczyk, Frank Z.

AU - Zheng, Wenxin -

PY - 2000

Y1 - 2000

N2 - Objective. The aim of this study was to investigate the role of apoptosis during progestin therapy for the treatment of endome-trial hyperplasia. Methods. Pre- and posttreatment paraffin-embedded endome-trial tissue samples from 19 Women with endometrial hyperplasia were examined for changes in glandular cellularity and apoptotic activity related to the administration of progestins. Twelve patients were successfully treated with progestin therapy and 7 patients failed treatment. Glandular cellularity was assessed based on calculating the average number of cells per gland obtained on histologic examination of hematoxylin and eosin stained tissue sections. Apoptotic activity was assessed on the same tissue sections by counting the average number of apoptotic cells per 10 high power fields (hpf) using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The effects of progesterone on apoptotic activity in a low-grade endometrial adenocarcinoma cell line (Ishikawa cells) was also examined using an ELISA cell death detection kit. Results. Glandular cellularity significantly decreased with pro-gestin therapy in both treatment outcome groups. The reduction in cells per gland was significantly greater in the group of successfully treated cases compared to the treatment failures (P = 0.005). However, within the successfully treated group, in situ detection of apoptotic cells using the TUNEL assay showed no statistical difference between pre- and posttreatment endometrial samples. Interestingly, a significant decrease in apoptosis was found in posttreatment samples of the group with persistent hyperplasia. The average number of apoptotic cells detected in 10 hpf was reduced from 7.9 prior to treatment to 3.1 after progestin therapy (P = 0.03). In the progesterone-treated Ishikawa cell line, an increase in apoptotic activity started at 24 h, reached a peak at 48 h, and continued up to 72 h of hormone treatment. At 48 h, apoptotic activity was 42.6% greater than in the untreated control (P = 0.04). By 72 h of progesterone treatment, apoptosis was 37.2% greater in the treated cells compared to the noninoculated cells (P = 0.04). Conclusions. Progestin-induced apoptosis may occur during the early period of treatment for endometrial hyperplasia. Compared to the fully responsive group, persistent endometrial hyperplasia may have intrinsically different molecular mechanisms in response to progestin therapy. (C) 2000 Academic Press.

AB - Objective. The aim of this study was to investigate the role of apoptosis during progestin therapy for the treatment of endome-trial hyperplasia. Methods. Pre- and posttreatment paraffin-embedded endome-trial tissue samples from 19 Women with endometrial hyperplasia were examined for changes in glandular cellularity and apoptotic activity related to the administration of progestins. Twelve patients were successfully treated with progestin therapy and 7 patients failed treatment. Glandular cellularity was assessed based on calculating the average number of cells per gland obtained on histologic examination of hematoxylin and eosin stained tissue sections. Apoptotic activity was assessed on the same tissue sections by counting the average number of apoptotic cells per 10 high power fields (hpf) using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The effects of progesterone on apoptotic activity in a low-grade endometrial adenocarcinoma cell line (Ishikawa cells) was also examined using an ELISA cell death detection kit. Results. Glandular cellularity significantly decreased with pro-gestin therapy in both treatment outcome groups. The reduction in cells per gland was significantly greater in the group of successfully treated cases compared to the treatment failures (P = 0.005). However, within the successfully treated group, in situ detection of apoptotic cells using the TUNEL assay showed no statistical difference between pre- and posttreatment endometrial samples. Interestingly, a significant decrease in apoptosis was found in posttreatment samples of the group with persistent hyperplasia. The average number of apoptotic cells detected in 10 hpf was reduced from 7.9 prior to treatment to 3.1 after progestin therapy (P = 0.03). In the progesterone-treated Ishikawa cell line, an increase in apoptotic activity started at 24 h, reached a peak at 48 h, and continued up to 72 h of hormone treatment. At 48 h, apoptotic activity was 42.6% greater than in the untreated control (P = 0.04). By 72 h of progesterone treatment, apoptosis was 37.2% greater in the treated cells compared to the noninoculated cells (P = 0.04). Conclusions. Progestin-induced apoptosis may occur during the early period of treatment for endometrial hyperplasia. Compared to the fully responsive group, persistent endometrial hyperplasia may have intrinsically different molecular mechanisms in response to progestin therapy. (C) 2000 Academic Press.

KW - Apoptosis

KW - Endometrial cancer

KW - Endometrial hyperplasia

KW - Progestin

UR - http://www.scopus.com/inward/record.url?scp=0033762272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033762272&partnerID=8YFLogxK

U2 - 10.1006/gyno.2000.5955

DO - 10.1006/gyno.2000.5955

M3 - Article

C2 - 11063639

AN - SCOPUS:0033762272

VL - 79

SP - 169

EP - 176

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -